Epigenetics in neurodegeneration: A new layer of complexity

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 35, Issue 2, 2011, Pages 348-355

  Marques, Sueli C F ^a,b   Oliveira, Catarina R ^a,c   Pereira, Claudia M F ^a,c   Outeiro, Tiago F ^b,d  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^c UNIVERSITY OF COIMBRA   (Portugal)

^d INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

Author keywords

Alzheimer's disease; Epigenetics; Etiology; Molecular mechanisms; Neurodegeneration; Parkinson's disease

Indexed keywords

DNA; HISTONE DEACETYLASE INHIBITOR;

AGING; ALZHEIMER DISEASE; ARTICLE; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMATIN STRUCTURE; CLINICAL FEATURE; COGNITIVE DEFECT; DNA METHYLATION; DNA SEQUENCE; DNA STRUCTURE; EPIGENETICS; GENE ACTIVITY; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; HUNTINGTON CHOREA; MOLECULAR PATHOLOGY; MORBIDITY; MUTATIONAL ANALYSIS; NEUROLOGIC EXAMINATION; NEUROPATHOLOGY; NONHUMAN; ONSET AGE; PARKINSON DISEASE; PHENOTYPIC PLASTICITY; PREVALENCE;

AGING; ALZHEIMER DISEASE; EPIGENESIS, GENETIC; HUMANS; INHERITANCE PATTERNS; NERVE DEGENERATION; NEURODEGENERATIVE DISEASES; PARKINSON DISEASE; POLYMORPHISM, GENETIC; RISK FACTORS;

EID: 79952900959     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2010.08.008     Document Type: Article

References (85)

1. Abeliovich A., Beal M.F. REVIEW. Parkinsonism genes: culprits and clues. J Neurochem 2006, 99:1062-1072.
2. Alzheimer's Association 2009 Alzheimer's disease facts and figures. Alzheimers Dement 2009, 5:234-270.
3. Asada T. Prevention of Alzheimer's disease: putative nutritive factors. Psychogeriatrics 2007, 7:125-131.
4. Avramopoulos D. Review: Genetics of Alzheimer's disease: recent advances. Genome Med 2009, 1:34.
5. Belin A.C., Westerlund M. Parkinson's disease: a genetic perspective. FEBS J 2008, 275:1377-1383.
6. Bence N.F., Sampat R.P., Kopito R.R. Impairment of the ubiquitin-proteasome system by protein aggregation. Science 2001, 292:1552-1555.
7. Bertam L., Tanzi R. The genetic epidemiology of neurodegenerative disease. J Clin Investig 2005, 115:1449-1457.
8. Bjornsson H.T., Fallin M.D., Feinberg A.P. An integrated epigenetic and genetic approach to common human disease. Trends Genet 2004, 20:350-358.
9. Blandini F., Fancellu R., Martignoni E., Mangiagalli A., Pacchetti C., Samuele A., et al. Plasma homocysteine and l-dopa metabolism in patients with Parkinson disease. Clin Chem 2001, 47:1102-1104.
10. Bonini N.M., Giasson B.I. Snaring the function of α-synuclein. Cell 2005, 123:359-373.
11. Bossy-Wetzel E., Schwarzenbacher R., Lipton S.A. Molecular pathways to neurodegeneration. Nat Med 2004, 10:S2-S9.
12. Bottiglieri T., Godfrey P., Flynn T., Carney M.W., Toone B.K., Reynolds E.H. Cerebrospinal fluid S-adenosylmethionine in depression and dementia, effects of treatment with parenteral and oral S-adenosylmethionine. J Neurol Neurosurg Psychiatry 1990, 53:1096-1098.
13. Braak H., Del Tredici K., Rüb U., de Vos R.A., Jansen Steur E.N., Braak Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003, 24:197-211.
14. Brighina L., Frigerio R., Schneider N.K., Lesnick T.G., de Andrade M., Cunningham J.M., et al. Alpha-synuclein, pesticides, and Parkinson disease: a case-control study. Neurology 2008, 70:1461-1469.
15. Burke R.E., Dauer W.T., Vonsattel J.P.G. A critical evaluation of the Braak staging scheme for Parkinson's disease. Annu Neurol 2008, 64:485-491.
16. Cabrejo L., Guyant-Maréchal L., Laquerrière A., Vercelletto M., De la Fournière F., Thomas-Antérion C., et al. Phenotype associated with APP duplication in five families. Brain 2006, 129:2966-2976.
17. Carrasquillo M.M., Zou F., Pankratz V.S., Wilcox S.L., Ma L., Walker L.P., et al. Genetic variation in PCDH11X is associated with susceptibility to late-onset Alzheimer's disease. Nat Genet 2009, 41:192-198.
18. Chan D.K., Mok V., Ng P.W., Yeung J., Kwok J.B., Fang Z.M., et al. PARK2 mutations and clinical features in a Chinese population with early-onset Parkinson's disease. J Neural Transm 2008, 115:715-719.
19. Dauer W., Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003, 39:889-909.
20. De Marco E.V., Annesi G., Tarantino P., Nicoletti G., Civitelli D., Messina D., et al. DJ-1 is a Parkinson's disease susceptibility gene in southern Italy. Clin Genet 2010, 77:183-188.
21. Di Fede G., Catania M., Morbin M., Rossi G., Suardi S., Mazzoleni G., et al. A recessive mutation in the APP gene with dominant-negative effect on amyloidogenesis. Science 2009, 323:1473-1477.
22. Dolinoy D.C., Jirtle R.L. Environmental epigenomics in human health and disease. Environ Mol Mutagen 2008, 49:4-8.
23. Duan W., Ladenheim B., Cutler R.G., Kruman I.I., Cadet J.L., Mattson M.P. Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease. J Neurochem 2002, 80:101-110.
24. Ertekin-Taner N. Genetics of Alzheimer's disease: a centennial review. Neurol Clin 2007, 25:611-653.
25. Evangelou E., Maraganore D.M., Ioannidis J.P. Meta-analysis in genome-wide association datasets: strategies and application in Parkinson disease. PLoS ONE 2007, 2:e196.
26. Farrer M.J. Genetics of Parkinson disease: paradigm shifts and future prospects. Nat Rev Genet 2006, 7:306-318.
27. Forman M.S., Trojanowski J.Q., Lee V.M. Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs. Nat Med 2004, 10:1055-1063.
28. Fraga M.F., Esteller M. Epigenetics and aging: the targets and the marks. Trends Genet 2007, 23:413-418.
29. Fraga M.F., Ballestar E., Paz M.F., Ropero S., Setien F., Ballestar M.L., et al. Epigenetic differences arise during the lifetime of monozygotic twins. Proc Natl Acad Sci 2005, 102:10604-10609.
30. Francis Y.I., Fà M., Ashrafa H., Zhanga H., Staniszewskia A., Latchmanb D.S., et al. Dysregulation of histone acetylation in the APP/PS1 mouse model of Alzheimer's disease. J Alzheimers Dis 2009, 18:131-139.
31. Fuchs J., Tichopad A., Golub Y., Munz M., Schweitzer K.J., Wolf B., et al. Genetic variability in the SNCA gene influences alpha-synuclein levels in the blood and brain. FASEB J 2008, 22:1327-1334.
32. Funayama M., Li Y., Tsoi T.H., Lam C.W., Ohi T., Yazawa S., et al. Familial Parkinsonism with digenic parkin and PINK1 mutations. Mov Disord 2008, 23:1461-1465.
33. Fuso A., Seminara L., Cavallaro R.A., D'Anselmi F., Scarpa S. S-adenosylmethionine/homocysteine cycle alterations modify DNA methylation status with consequent deregulation of PS1 and BACE and beta-amyloid production. Mol Cell Neurosci 2005, 28:195-204.
34. Grupe A., Abraham R., Li Y., Rowland C., Hollingworth P., Morgan A., et al. Evidence for novel susceptibility genes for late-onset Alzheimer's disease from a genome-wide association study of putative functional variants. Hum Mol Genet 2007, 16:865-873.
35. Hardy J., Lewis P., Revesz T., Lees A., Paisan-Ruiz C. The genetics of Parkinson's syndromes: a critical review. Curr Opin Genet Dev 2009, 19:254-265.
36. Ho P.I., Ortiz D., Rogers E., Shea T.B. Multiple aspects of homocysteine neurotoxicity: glutamate excitotoxicity, kinase hyperactivation and DNA damage. J Neurosci Res 2002, 70:694-702.
37. http://www.who.int/hpr/ageing/ActiveAgingPolicyFrame.pdf.
38. Kennedy B.P., Bottiglieri T., Arning E., Ziegler M.G., Hansen L.A., Masliah E. Elevated S-adenosylhomocysteine in Alzheimer brain: influence on methyltransferases and cognitive function. J Neural Transm 2004, 111:547-567.
39. Khandhar S.M., Marks W.J. Epidemiology of Parkinson's disease. Dis Mon 2007, 53:200-205.
40. Klein C., Schlossmacher M.G. Parkinson disease, 10years after its genetic revolution: multiple clues to a complex disorder. Neurology 2007, 69:2093-2104.
41. Kontopoulos E., Parvin J.D., Feany M.B. Alpha-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity. Hum Mol Genet 2006, 15:3012-3023.
42. Kovalchuk O. Epigenetic research sheds new light on the nature of interactions between organisms and their environment. Environ Mol Mutagen 2008, 49:1-3.
43. Lahiri D.K., Maloney B., Zawia N.H. The LEARn model: an epigenetic explanation for idiopathic neurobiological diseases. Mol Psychiatry 2009, 14:992-1003.
44. Lau L.M.L., Breteler M.B. Epidemiology of Parkinson's disease. Lancet Neurol 2006, 5:525-535.
45. Lesage S., Brice A. Parkinson's disease: from monogenic form to genetic susceptibility factors. Hum Mol Genet 2009, 18:R48-R59.
46. Liu H., Liu W., Wu Y., Zhou Y., Xue R., Luo C., et al. Loss of epigenetic control of synuclein-{gamma} gene as a molecular indicator of metastasis in a wide range of human cancers. Cancer Res 2005, 65:7635-7643.
47. Luchsinger J.A., Mayeux R. Dietary factors and Alzheimer's disease. Lancet Neurol 2004, 3:579-587.
48. MacLeod D., Dowman J., Hammond R., Leete T., Inoue K., Abeliovich A. The familial Parkinsonism gene LRRK2 regulates neurite process morphology. Neuron 2006, 52:587-593.
49. Maraganore D.M., de Andrade M., Elbaz A., Farrer M.J., Ioannidis J.P., Krüger R., et al. Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease. Genetic Epidemiology of Parkinson's Disease (GEO-PD) Consortium. JAMA 2006, 296:661-670.
50. Mastroeni D, Grover A, Delvaux E, Whiteside C, Coleman PD, Rogers J. Epigenetic changes in Alzheimer's disease: decrements in DNA methylation. Neurobiology of Aging 2008; [Epub].
51. Mastroeni D., McKee A., Grover A., Rogers J., Coleman P.D. Epigenetic differences in cortical neurons from a pair of monozygotic twins discordant for Alzheimer's disease. PLoS ONE 2009, 4:e6617.
52. Mattson M.P., Magnus T. Ageing and neuronal vulnerability. Nat Rev Neurosci 2006, 7:278-294.
53. Mattson M.P., Shea T.B. Folate and homocysteine metabolism in neural plasticity and neurodegenerative disorders. Trends Neurosci 2003, 3:13-146.
54. Minati L., Edginton T., Bruzzone M.G., Giaccone G. Current concepts in Alzheimer's disease: a multidisciplinary review. Am J Alzheimers Dis Other Demen 2009, 24:95-121.
55. Mizuta I., Satake W., Nakabayashi Y., Ito C., Suzuki S., Momose Y., et al. Multiple candidate gene analysis identifies alpha-synuclein as a susceptibility gene for sporadic Parkinson's disease. Hum Mol Genet 2006, 15:1151-1158.
56. Outeiro T.F., Kontopoulos E., Altmann S.M., Kufareva I., Strathearn K.E., Amore A.M., et al. Sirtuin 2 inhibitors rescue a-synuclein-mediated toxicity in models of Parkinson's disease. Science 2007, 317:516-519.
57. Pacheco-Quinto J., de Turco E.B.R., DeRosa S., Howard A., Cruz-Sanchez F., Sambamurti K., et al. Hyperhomocysteinemic Alzheimer's mouse model of amyloidosis shows increased brain amyloid B peptide levels. Neurobiol Dis 2006, 22:651-656.
58. Peleg S., Sananbenesi F., Zovoilis A., Burkhardt S., Bahari-Javan S., Agis-Balboa R.C., et al. Altered histone acetylation is associated with age-dependent memory impairment in mice. Science 2010, 328(5979):753-756. May 7.
59. Ravaglia G., Forti P., Maioli F., Martelli M., Servadei L., Brunetti N., et al. Homocysteine and folate as risk factors for dementia and Alzheimer disease. Am J Clin Nutr 2005, 82:636-643.
60. Ray W.J., Ashall F., Goate A.M. Molecular pathogenesis of sporadic and familial forms of Alzheimer's disease. Mol Med Today 1998, 4:151-157.
61. Rocchi A., Pellegrini S., Siciliano G., Murri L. Causative and susceptibility genes for Alzheimer's disease: a review. Brain Res Bull 2003, 61:1-24.
62. Ross C.A., Poirier M.A. Protein aggregation and neurodegenerative disease. Nat Med 2004, 10:S10-S17.
63. Santibáñez M., Bolumar F., García A.M. Occupational risk factors in Alzheimer's disease: a review assessing the quality of published epidemiological studies. Occup Environ Med 2007, 64:723-732.
64. Scarpa S., Fuso A., D'Anselmi F., Cavallaro R.A. Presenilin 1 gene silencing by S-adenosylmethionine: a treatment for Alzheimer disease?. FEBS Lett 2003, 541:145-148.
65. Schjeide B.M., Hooli B., Parkinson M., Hogan M.F., DiVito J., Mullin K., et al. GAB2 as an Alzheimer disease susceptibility gene: follow-up of genomewide association results. Arch Neurol 2009, 66:250-254.
66. Seshadri S., Beiser A., Selhub J., Jacques P.F., Rosenberg I.H., D'Agostino R.B., et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. New Engl J Med 2002, 346:476-483.
67. Silva P.N.O., Gigek C.O., Leal M.F., Bertolucci P.H.F., de Labio R.W., Payão S.L.M., et al. Promoter methylation analysis of SIRT3, SMARCA5, HTERT and CDH1 genes in aging and Alzheimer's disease. J Alzheimers Dis 2008, 13:173-176.
68. Sleegers K., Brouwers N., Gijselinck I., Theuns J., Goossens D., Wauters J., et al. APP duplication is sufficient to cause early onset Alzheimer's dementia with cerebral amyloid angiopathy. Brain 2006, 129:2977-2983.
69. Sontag E., Hladik C., Montgomery L., Luangpirom A., Mudrak I., Ogris E., et al. Downregulation of protein phosphatase 2A carboxyl methylation and methyltransferase may contribute to Alzheimer disease pathogenesis. J Neuropathol Exp Neurol 2004, 63:1080-1091.
70. Sontag E., Nunbhakdi-Craig V., Sontag J.M., Diaz-Arrastia R., Ogris E., Dayal S., et al. Protein phosphatase 2A methyltransferase links homocysteine metabolism with tau and amyloid precursor protein regulation. J Neurosci 2007, 27:2751-2759.
71. Soto C. Unfolding the role of protein misfolding in neurodegenerative diseases. Nat Rev Neurosci 2003, 4:49-60.
72. Stozicka Z., Zilka N., Novak M. Review. Risk and protective factors for sporadic Alzheimer's disease. Acta Virol 2007, 51:205-222.
73. Tanzi R.E., Bertram L. New frontiers in Alzheimer's disease genetics. Neuron 2001, 32:181-184.
74. Taylor J.P., Hardy J., Fischbeck K.H. Toxic proteins in neurodegenerative disease. Science 2002, 296:1991-1995.
75. Tobin J.E., Latourelle J.C., Lew M.F., Klein C., Suchowersky O., Shill H.A., et al. Haplotypes and gene expression implicate the MAPT region for Parkinson disease: the GenePD Study. Neurology 2008, 71:28-34.
76. Tohgi H., Utsugisawa K., Nagane Y., Yoshimura M., Genda Y., Ukitsu M. Reduction with age in methylcytosine in the promoter region -224~-101 of the amyloid precursor protein gene in autopsy human cortex. Mol Brain Res 1999, 70:288-292.
77. van Vliet J., Oates N.A., Whitelaw E. Epigenetic mechanisms in the context of complex diseases. Cell Mol Life Sci 2007, 64:1531-1538.
78. Voutsinas G.E., Stavrou E.F., Karousos G., Dasoula A., Papachatzopoulou A., Syrrou M., et al. Allelic imbalance of expression and epigenetic regulation within the alpha-synuclein wild-type and p.Ala53Thr alleles in Parkinson disease. Hum Mutat 2010, 31:685-691.
79. Wang S.-C., Oelze B., Schumacher A. Age-specific epigenetic drift in late-onset Alzheimer's disease. Public Libr Sci One 2008, 3:e2698.
80. Weih M., Wiltfang J., Kornhuber J. Non-pharmacologic prevention of Alzheimer's disease: nutritional and life-style risk factors. J Neural Transm 2007, 114:1187-1197.
81. Weintraub D., Comella C.L., Horn S. Parkinson's disease-part 1: pathophysiology, symptoms, burden, diagnosis, and assessment. Am J Manage Care 2008, 14:S40-S48.
82. Wood-Kaczmar A., Gandhi S., Wood N.W. Understanding the molecular causes of Parkinson's disease. Trends Mol Med 2006, 12:521-528.
83. Wu J., Basha M.R., Brock B., Cox D.P., Cardozo-Pelaez F., McPherson C.A., et al. Alzheimer's disease (AD)-like pathology in aged monkeys after infantile exposure to environmental metal lead (Pb): evidence for a developmental origin and environmental link for AD. J Neurosci 2008, 28:3-9.
84. Zádori D., Geisz A., Vámos E., Vécsei L., Klivényi P. Valproate ameliorates the survival and the motor performance in a transgenic mouse model of Huntington's disease. Pharmacol Biochem Behav 2009, 94:148-153.
85. Zhao W., Liu H., Liu W., Wu Y., Chen W., Jiang B., et al. Abnormal activation of the synuclein-gamma gene in hepatocellular carcinomas by epigenetic alteration. Int J Oncol 2006, 28:1081-1088.